Inactive Instrument

CytRx Corporation Share Price Nasdaq

Equities

US2328286081

Biotechnology & Medical Research

Sales 2022 - Sales 2023 - Capitalization 644K 51.23M
Net income 2022 -4M -318M Net income 2023 - 0 EV / Sales 2022 -
Net cash position 2022 1.15M 91.17M Net cash position 2023 2.04M 162M EV / Sales 2023 -
P/E ratio 2022
-1.05 x
P/E ratio 2023
1.91 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 99.44%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 55 09/01/22
Director of Finance/CFO 72 30/09/07
Corporate Secretary - -
Members of the board TitleAgeSince
Chairman 55 28/07/21
Director/Board Member 64 26/07/22
Director/Board Member 69 11/07/17
More insiders
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.
More about the company